List of Excipients in Branded Drug FOCALIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	FOCALIN	dexmethylphenidate hydrochloride	0078-0380	CELLULOSE, MICROCRYSTALLINE
Novartis Pharmaceuticals Corporation	FOCALIN	dexmethylphenidate hydrochloride	0078-0380	FD&C BLUE NO. 1
Novartis Pharmaceuticals Corporation	FOCALIN	dexmethylphenidate hydrochloride	0078-0380	LACTOSE MONOHYDRATE
Novartis Pharmaceuticals Corporation	FOCALIN	dexmethylphenidate hydrochloride	0078-0380	MAGNESIUM STEARATE
Novartis Pharmaceuticals Corporation	FOCALIN	dexmethylphenidate hydrochloride	0078-0380	SODIUM STARCH GLYCOLATE TYPE A POTATO
Novartis Pharmaceuticals Corporation	FOCALIN	dexmethylphenidate hydrochloride	0078-0380	STARCH, CORN

Focalin Excipient Strategy and Commercial Opportunities

Last updated: September 2, 2026

Focalin and Focalin XR contain dexmethylphenidate hydrochloride, the d-enantiomer of methylphenidate. The immediate-release product uses a conventional tablet platform, while Focalin XR uses a dual-pulse modified-release bead system. The strongest excipient opportunities are therefore in abuse-deterrent delivery, pediatric acceptability, dose flexibility, alcohol-resistant release, and lower-cost manufacturing rather than simple substitution of inactive ingredients.

Focalin is a Schedule II stimulant approved for attention deficit hyperactivity disorder. Its commercial opportunity is concentrated in differentiated generic, authorized-generic, pediatric, and modified-release products. Any new formulation must preserve dexmethylphenidate exposure, dose proportionality, release timing, and controlled-substance manufacturing controls.[1][2]

What are the Focalin and Focalin XR dosage forms?

Focalin is an immediate-release tablet. Focalin XR is a modified-release capsule containing dexmethylphenidate hydrochloride in a dual-bead delivery system.

Product	Active ingredient	Dosage form	Strengths	Release profile	FDA status
Focalin	Dexmethylphenidate hydrochloride	Immediate-release tablet	2.5, 5, 10 mg	Rapid release	Approved NDA product
Focalin XR	Dexmethylphenidate hydrochloride	Extended-release capsule	5, 10, 15, 20, 25, 30, 35, 40 mg	Two release pulses approximately separated over the dosing interval	Approved NDA product
Generic dexmethylphenidate	Dexmethylphenidate hydrochloride	Tablet and extended-release capsule	Multiple strengths	Equivalent IR or ER performance required	ANDA products marketed

Focalin XR capsules can be swallowed whole or opened and sprinkled on applesauce under label instructions. The contents should not be crushed, chewed, or divided because those actions may alter the intended release profile.[2]

Which excipients are used in Focalin?

The immediate-release Focalin tablet uses standard solid-dose excipients selected for manufacturability, tablet integrity, disintegration, and dose uniformity. Labeling identifies inactive ingredients that include lactose monohydrate, pregelatinized starch, microcrystalline cellulose, magnesium stearate, and talc, with product-specific coating or color components depending on strength.[1]

The commercial implications are direct:

• Lactose supports bulk, flow, and compression but creates a route for lactose-free positioning.
• Pregelatinized starch supports binding and disintegration.
• Microcrystalline cellulose supports tablet hardness and content uniformity.
• Magnesium stearate improves lubrication but can slow wetting or dissolution when overused.
• Talc and coating materials support processability and product identification.

For a generic immediate-release product, excipient changes are usually feasible if dissolution, stability, assay, content uniformity, impurities, and bioequivalence remain acceptable. The principal regulatory risk is not the identity of an individual excipient. It is the effect of the complete formulation on dexmethylphenidate release and absorption.

What excipients are used in Focalin XR?

Focalin XR uses a multiparticulate bead system. The capsule contains immediate-release and delayed-release portions designed to produce two dexmethylphenidate release pulses. The product uses inactive ingredients associated with bead manufacture, coating, capsule filling, and release control, including sugar-based bead materials, polymers, cellulose-derived materials, talc, titanium dioxide, and capsule-shell components, as identified in product labeling.[2]

The key formulation elements are:

Formulation function	Excipient or material class	Commercial purpose
Inert bead core	Sugar or other starter-particle system	Provides a uniform substrate for drug layering
Drug layering	Film-forming binder or polymer	Deposits dexmethylphenidate consistently on the bead
Immediate-release fraction	Rapidly dissolving coating or uncoated drug layer	Produces the first exposure pulse
Delayed-release fraction	Functional polymer coating	Delays dissolution until the target intestinal environment
Anti-tacking and coating aid	Talc or comparable processing aid	Supports uniform coating and reduces agglomeration
Capsule shell	Gelatin or hypromellose	Provides oral unit-dose presentation
Colorant or opacifier	Titanium dioxide or other permitted colorant	Supports identification, light protection, and strength differentiation

The dual-pulse architecture is more difficult to copy than a conventional extended-release matrix tablet. A generic sponsor must control bead size, drug-layer thickness, polymer weight gain, coating uniformity, capsule fill composition, dissolution, and stability. These manufacturing variables create a higher barrier than the nominal inactive-ingredient list suggests.

How should an excipient strategy for Focalin be designed?

A commercially viable strategy should begin with the target product profile rather than with excipient replacement. Four platforms have the highest practical value.

1. Lactose-free immediate-release tablets

A lactose-free tablet could replace lactose monohydrate with mannitol, anhydrous dibasic calcium phosphate, spray-dried mannitol, or a combination of microcrystalline cellulose and coprocessed excipients.

The target advantages are:

• Reduced concern for patients with lactose intolerance.
• More flexible global formulation strategy.
• Potentially improved moisture control with selected fillers.
• A differentiated label for pharmacies, hospitals, and pediatric prescribers.

The main development challenge is maintaining comparable disintegration and dissolution after changing the filler and binder system. A lactose-free product would not automatically receive a separate clinical advantage. Its value would depend on reliable supply, tolerability positioning, and payer access.

2. Pediatric-friendly sprinkle or dispersible delivery

Focalin XR already permits sprinkling capsule contents on applesauce. A stronger product concept would use taste-masked multiparticulates, orally disintegrating mini-tablets, or a ready-to-administer granule system.

Relevant excipient technologies include:

• Methacrylate or ethylcellulose taste-masking films.
• Lipid or polymer barriers that resist saliva but dissolve in the stomach.
• Mannitol-based orally disintegrating systems.
• Low-moisture granulation platforms.
• Flavor systems compatible with controlled substances and pediatric use.

Taste masking must not delay gastric release or reduce dexmethylphenidate bioavailability. Multiparticulate delivery also requires control of dose recovery from food, spoon, cup, and oral syringe administration.

3. Alcohol-resistant extended release

Alcohol-induced dose dumping is a major risk for oral extended-release stimulants. A formulation using pH-independent or alcohol-resistant polymer coatings could reduce release acceleration in ethanol-containing media.

Potential material classes include:

• Ethylcellulose membrane systems.
• Methacrylate copolymers with controlled permeability.
• Insoluble polymer blends.
• Multiparticulate coatings with higher mechanical strength.
• Osmotic or reservoir systems that separate drug release from alcohol exposure.

The regulatory value is strongest when the formulation shows robust dissolution across pH, agitation, ethanol concentration, and mechanical stress conditions. An alcohol-resistant claim would require a disciplined clinical and in vitro package and may support new formulation patent claims.

4. Lower-cost dual-pulse bead manufacturing

The largest generic opportunity may be process optimization rather than a new patient-facing excipient. A sponsor could reduce cost by using:

• Higher-solids aqueous coating.
• Continuous fluid-bed coating.
• Smaller bead size with tighter particle-size distribution.
• A single coating platform for multiple strengths.
• More efficient drug-layering equipment.
• Reduced coating weight gain without loss of release control.
• Excipient standardization across Focalin XR strengths.

The value lies in yield, throughput, batch release, and supply continuity. A process patent may protect coating sequence, polymer ratios, bead populations, or manufacturing parameters even when the finished-product excipients are conventional.

What formulation patents protect Focalin and Focalin XR?

The historical Focalin XR patent position centered on the extended-release delivery system and its pulsed release profile rather than on a broad proprietary excipient molecule. The relevant intellectual-property risks include:

IP category	Protected subject matter	Relevance to a competing product
Drug composition	Dexmethylphenidate hydrochloride	Limited value after active-ingredient patent expiration
Multiparticulate delivery	Bead architecture and release fractions	May affect non-infringement and formulation design
Coating system	Polymer layers, permeability, and release timing	Important for XR development
Method of use	ADHD treatment and dosing schedules	Relevant to labeling and Paragraph IV strategy
Manufacturing process	Drug layering, coating, bead separation, and capsule filling	Can create practical manufacturing barriers
Regulatory listing	Patents submitted to the Orange Book	Determines Paragraph IV exposure for ANDA applicants

Focalin XR had historical extended-release patent protection associated with U.S. Patent No. 6,322,819. The commercial exclusivity period for the branded product has ended, and generic dexmethylphenidate products are marketed. Current freedom-to-operate analysis must rely on the live patent record, Orange Book listings, FDA approval history, and claim construction rather than on the existence of the original XR patent alone.[3][4]

When did Focalin lose exclusivity?

Focalin immediate-release exclusivity has ended, and generic dexmethylphenidate tablets are available. Focalin XR also faces generic competition, including extended-release capsule products approved through the ANDA pathway.[3]

Exclusivity issue	Commercial position
Active ingredient	Generic dexmethylphenidate products are available
Immediate-release tablets	Mature generic market
Extended-release capsules	Generic competition exists
Pediatric exclusivity	Historical pediatric exclusivity is no longer a current barrier
New formulation opportunity	Requires separate FDA approval and differentiated IP
Controlled-substance status	Continues to affect manufacturing, distribution, inventory, and diversion controls

The practical market question is no longer whether basic dexmethylphenidate can be commercialized. It is whether a new formulation can improve adherence, administration, abuse resistance, supply reliability, or cost enough to justify development and market access investment.

What is the Orange Book status of Focalin?

Focalin and Focalin XR are FDA-approved prescription products listed in the Orange Book framework. Orange Book information distinguishes the reference listed drug, dosage form, strength, approval pathway, and patent or exclusivity information submitted for the product.[3]

For an ANDA sponsor, the key regulatory routes are:

• Paragraph I certification when no relevant patent information is listed.
• Paragraph II certification when a listed patent has expired.
• Paragraph III certification when the applicant will wait for patent expiration.
• Paragraph IV certification when the applicant asserts that a listed patent is invalid, unenforceable, or not infringed.

A formulation change involving excipients does not remove the need to evaluate listed patents. A product can avoid one claim directed to a specific polymer or bead structure while remaining exposed to broader claims covering release behavior, multiparticulate composition, or treatment methods.

Which companies are challenging Focalin exclusivity?

Generic competition is led by ANDA applicants and manufacturers supplying dexmethylphenidate immediate-release tablets and extended-release capsules. The market includes large generic companies and authorized or contract manufacturers, but product-level commercial share is not consistently disclosed in public filings.

The competitive set includes:

• Generic immediate-release dexmethylphenidate tablets.
• Generic extended-release dexmethylphenidate capsules.
• Methylphenidate immediate-release and extended-release products.
• Amphetamine mixed salts.
• Lisdexamfetamine.
• Nonstimulant ADHD therapies such as atomoxetine, viloxazine, and guanfacine.

For an excipient-driven entrant, the closest competitors are generic Focalin XR products, not all ADHD drugs. The product must demonstrate a meaningful advantage in administration, release control, supply, or price.

What generic launch risks exist for a new Focalin formulation?

A new formulation faces five principal risks.

Bioequivalence risk

Modified-release products require more than a conventional single-dose comparison. The sponsor must manage pharmacokinetic similarity, partial AUC intervals, peak exposure, food effects, and dissolution performance. Differences in bead coating can produce clinically meaningful changes in early or late exposure.

CMC risk

The critical quality attributes include assay, content uniformity, bead-size distribution, drug-layer uniformity, coating thickness, dissolution at multiple time points, impurities, moisture, and capsule fill weight.

Controlled-substance risk

Dexmethylphenidate is a Schedule II controlled substance. Manufacturing sites must meet Drug Enforcement Administration requirements for procurement, inventory, security, recordkeeping, quotas, and distribution. These obligations raise working-capital and operational costs.[5]

IP risk

A new excipient combination may still infringe a claim directed to the delivery architecture or release profile. Patent clearance should cover composition, process, use, and regulatory listing exposure.

Market-access risk

Payers may treat a lactose-free, sprinkle, or alcohol-resistant product as therapeutically interchangeable with lower-cost generic capsules. Without a distinct National Drug Code strategy, formulary preference, or clinical administration advantage, the product may face rapid price compression.

How strong is the Focalin patent estate?

The basic Focalin patent estate is commercially weaker than during the branded exclusivity period because immediate-release and extended-release generic products are available. The remaining strategic value is concentrated in narrow formulation, process, device, and method claims.

Patent layer	Current strategic strength
Basic dexmethylphenidate composition	Low
Conventional immediate-release tablet	Low
Dual-pulse multiparticulate delivery	Moderate for narrowly drafted claims
Specific polymer coating system	Moderate if claim scope is commercially relevant
Alcohol-resistant release	Potentially strong for a genuinely differentiated formulation
Pediatric delivery system	Potentially strong if supported by formulation and use claims
Manufacturing process	Moderate to strong where process substitution is difficult
Method-of-use claims	Variable and often vulnerable to label-based design-around

A new entrant should avoid relying on a single excipient patent. A layered estate covering formulation composition, manufacturing process, dissolution profile, administration method, and packaging provides stronger commercial protection.

What licensing deals could support a Focalin excipient strategy?

The most relevant licensing targets are technology owners with capabilities in:

• Multiparticulate coating.
• Taste masking.
• Orally disintegrating dosage forms.
• Abuse-deterrent stimulant delivery.
• Continuous fluid-bed processing.
• Controlled-substance contract manufacturing.
• Pediatric flavor and administration systems.

A license is most valuable when it includes freedom to operate, development support, scale-up rights, and commercial manufacturing access. A patent-only license may not solve the principal challenge if the technology cannot reproduce the required dexmethylphenidate release profile at commercial scale.

Potential deal structures include an upfront payment for formulation rights, milestone payments tied to bioequivalence and approval, and royalties linked to net sales. For a mature generic market, a contract development and manufacturing agreement may be more economical than a broad platform license.

What FDA regulatory pathway applies to a new Focalin excipient product?

A product that is pharmaceutically equivalent and bioequivalent to Focalin or Focalin XR generally uses the ANDA pathway. A materially different dosage form, delivery system, or clinical claim may require a 505(b)(2) application.[6]

Product concept	Likely pathway
IR tablet with different filler	ANDA if equivalence requirements are met
XR capsule with alternative coating system	ANDA if reference-product equivalence is established
Sprinkle granules with new administration design	ANDA or 505(b)(2), depending on sameness and data
Abuse-deterrent formulation with new performance claims	Often 505(b)(2) or a product-specific regulatory strategy
New liquid, patch, implant, or device combination	Likely 505(b)(2) or another new drug application route

FDA review will focus on the total product performance, not whether each excipient is individually familiar. Novel excipients, new routes of administration, or pediatric exposure concerns can expand the toxicology and clinical package.

What revenue exposure exists for Focalin?

Public company filings generally do not isolate Focalin revenue from broader ADHD or central-nervous-system portfolios. The commercial exposure is therefore best assessed through market structure rather than a single reliable branded-sales figure.

Revenue potential is highest in the following segments:

1. Premium pediatric administration products.
2. Extended-release products with stable supply and low substitution friction.
3. Authorized-generic or co-branded supply arrangements.
4. Institutional and public-sector contracts seeking predictable stimulant supply.
5. Products with differentiated abuse-deterrent or alcohol-resistant performance.

A conventional lactose-free tablet would likely compete mainly on procurement and tolerability positioning. A taste-masked, sprinkle-compatible, abuse-resistant, or supply-secure extended-release product offers greater pricing potential.

How does Focalin compare with competing ADHD formulations?

Product category	Main release strategy	Excipient opportunity	Competitive pressure
Focalin IR	Immediate-release tablet	Lactose-free, orally disintegrating, low-cost manufacturing	High
Focalin XR	Dual-pulse multiparticulate capsule	Taste masking, alcohol resistance, bead-process efficiency	High but technically differentiated
Methylphenidate ER	Matrix, osmotic, or multiparticulate systems	Delivery-specific reformulation	High
Lisdexamfetamine	Prodrug capsule or chewable	Taste, chewability, pediatric administration	High
Amphetamine mixed salts ER	Multiparticulate release	Release control and sprinkle systems	High
Nonstimulant products	Immediate or extended oral delivery	Taste, liquid dosing, pediatric adherence	Moderate

Focalin XR’s most defensible technical niche is a dexmethylphenidate product that improves administration without changing the intended dual-pulse exposure pattern.

What geographic coverage is available for an excipient-based Focalin product?

United States commercialization requires FDA approval, DEA compliance, controlled-substance quota planning, and Orange Book and labeling analysis. Outside the United States, market access depends on national marketing authorization, local patent status, controlled-drug rules, pediatric requirements, and reference-product availability.

The most portable formulation assets are:

• Taste-masked multiparticulates.
• Lactose-free tablets.
• Standardized coating processes.
• Alcohol-resistant release technology.
• Moisture-stable capsule systems.

Patent filings should prioritize the United States, European Union, Canada, Japan, Australia, and high-volume Latin American markets. Manufacturing-process protection may be more valuable in jurisdictions where product claims are narrow or difficult to enforce.

Key Takeaways

• Focalin is dexmethylphenidate; Focalin XR uses a dual-pulse multiparticulate delivery system.
• The immediate-release product is relatively easy to formulate around, while the extended-release product has greater coating and manufacturing complexity.
• The strongest excipient opportunities are pediatric taste masking, sprinkle delivery, lactose-free dosage forms, alcohol-resistant release, and process-cost reduction.
• Generic competition has ended basic Focalin exclusivity. Commercial success requires differentiation beyond ordinary excipient substitution.
• A new product may use an ANDA if it meets sameness and bioequivalence requirements. Materially different delivery systems may require a 505(b)(2) pathway.
• Controlled-substance compliance, quota management, and diversion controls are material commercial barriers.
• A layered patent estate should cover excipient composition, bead architecture, manufacturing process, release profile, administration method, and packaging.
• Public filings do not reliably isolate Focalin revenue, so opportunity assessment should focus on differentiated product economics and market access.

FAQs

Can lactose be removed from Focalin tablets?

Yes. Lactose can be replaced with mannitol, microcrystalline cellulose, dibasic calcium phosphate, or a coprocessed filler system, subject to dissolution, stability, content uniformity, and bioequivalence requirements.

Can Focalin XR beads be mixed into water?

The approved label permits sprinkling the capsule contents on applesauce, but it does not establish unrestricted mixing in water. Any water-dispersible product would require its own formulation, administration, and regulatory evaluation.[2]

Is an abuse-deterrent Focalin product commercially viable?

Potentially, but the product would need measurable resistance to manipulation or alcohol-induced dose dumping, a credible regulatory pathway, and payer or prescriber demand sufficient to offset development and manufacturing costs.

Which excipient is most important in Focalin XR?

The release-controlling polymer coating is most important because coating composition and weight gain determine the timing and robustness of the second dexmethylphenidate pulse.

Can a generic Focalin XR manufacturer use a different polymer system?

Yes, if the resulting product meets applicable equivalence, dissolution, stability, labeling, and patent requirements. A different polymer does not by itself avoid claims directed to broader release architecture or performance.

References

1. U.S. Food and Drug Administration. (2023). Focalin (dexmethylphenidate hydrochloride) tablets: Prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2023). Focalin XR (dexmethylphenidate hydrochloride) extended-release capsules: Prescribing information. FDA/DailyMed.

3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Patent and Trademark Office. (2001). U.S. Patent No. 6,322,819, controlled-release formulations of dexmethylphenidate. USPTO.

5. U.S. Drug Enforcement Administration. (2024). Controlled substance schedules and regulatory requirements for Schedule II stimulants. U.S. Department of Justice.

6. U.S. Food and Drug Administration. (2024). Applications covered by Section 505(b)(2). FDA.